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In February 2018 the international debate on antidepressant withdrawal was 
reignited. In response to a letter published in The Times by Davies et al. on the benefits 
and harms of antidepressants, the Royal College of Psychiatrists publicly stated that 
‘[for] the vast majority of patients any unpleasant symptoms experienced on 
discontinuing antidepressants have resolved within two weeks of stopping 
treatment’.i 
  
To support this claim, the College referred to the NICE guidelines, which state that 
‘[withdrawal] symptoms are usually mild and self-limiting over about 1 week’.ii 
 
When Davies et al. issued an FoI appeal to NICE requesting evidence for its one-week 
claim, NICE were only able to provide two short review articles, neither of which 
support NICE's one-week claim, while both cite numerous sources that contradict it.iii 
 
NICE's current position on antidepressant withdrawal (first established in 2004), was 
in our view not only advanced on insufficient evidence but is now widely countered 
by subsequent research. The following studies, using a range of methodologies, all 
show that many people experience withdrawal for longer than one week (e.g. for over 
2 weeks in 55% of patients,iv for at least 6 weeks in 40%,v at least 12 weeks in 25%vi 
and between 1 and 13 weeks in 58%,vii with other studies finding mean durations of 
11 daysviii and 43 daysix). 
 
Examples of longer durations, beyond a year, are reported by two recent, real life 
samples of people experiencing difficulties with withdrawal - i.e. for 38.6% (n=185)x 
and for a mean duration of 90.5 weeks (N = 97).xi    
 
Systematic reviews of withdrawal also concur, with one of the largest concluding that 
withdrawal symptoms ‘typically ensued within a few days from discontinuation and 
lasted a few weeks, also with gradual tapering. Late onset and/or a longer persistence 
of disturbances occurred as well’, xii  and another stating that while withdrawal 
reactions ‘typically occur within a few days from drug discontinuation and last a few 
weeks… many variations are possible, including late onset and/or longer persistence 
of disturbances’. xiii  The most recent systematic review, by Davies and Read, also 
concluded, on the basis of 14 studies of varied methodology, that around half of users 
experience withdrawal when trying to stop or reduce their antidepressants, that 
nearly half of these (46%) report their withdrawal as severe and that reports of 
symptoms lasting several months are common across many recent studies (see 
duration examples above).xiv 
 
That the evidence base contradicts NICE’s official position on antidepressant 
withdrawal, raises concerns for the substantial number of antidepressant users who 
will experience withdrawal for a longer duration than current guidelines recognise. 
Assuming doctors abide by such guidelines, we believe many people may have their 
antidepressant withdrawal misdiagnosed – e.g. as relapse or as a failure to respond to 
treatment – with antidepressants either being reinstated, switched or doses increased 
as a consequence. These practices, if routinely enacted, would help partly explain why 
the average time a person spends on an antidepressant has doubled in the U.K. since 
the guidelines were introduced in 2004,xv xvi why antidepressant prescriptions are 
rising overall and why patients regularly report their withdrawal not being properly 
acknowledged, understood and managed by doctors.xvii xviii It is also concerning that 
when pooling the results of two recent surveys, fewer than 2% of approximately 3000 
patients were able to recall being told anything about withdrawal 
effects, dependence, or potential difficulties discontinuing. xix xx 
  
It is of concern that antidepressants are causing withdrawal effects that can be long-
lasting and severe, and that this is not being sufficiently recognised by current clinical 
guidelines and, by extension, many prescribers. As NICE is now in the process of 
updating its depression guidelines, we call upon NICE and the Royal Colleges to revise 
their practice guidelines and recommendations to bring them in line with the scientific 
evidence base.  
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